Omnicol

Quick links to important sections

Omnicol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omnicol

What is Omnicol? A Fixed-Dose Combination Anti-Infective

Property Description
Active Ingredients Framycetin, Polymyxin B, Oxedrine, Phenylmercuric Nitrate
Form Specialized liquid preparations (e.g., solutions, suspensions)
Pharmacological Class Fixed-dose combination anti-infective and sympathomimetic
Common Use Localized infection control and symptom relief (topical)
Origin Synthetic/Semi-synthetic

What is Omnicol and What Type of Medicine Is It?

Omnicol is a fixed-dose combination (FDC) pharmaceutical preparation designed for topical application, classified broadly as a multi-component anti-infective and sympathomimetic agent. It is a synthetic/semi-synthetic medicine typically formulated as specialized liquid preparations, such as ophthalmic or otic solutions. Its FDC status means it combines distinct therapeutic ingredients to simultaneously address both the infectious cause and the symptomatic effects of a localized issue. For instance, the sympathomimetic component, Oxedrine, has the ability to produce localized vasoconstriction. This means the medicine helps ease swelling and congestion by causing small blood vessels in the treated area to narrow.


Composition and Combined Therapeutic Benefit

The efficacy of Omnicol is rooted in its blend of four distinct active ingredients [INN]: the antibiotics Framycetin and Polymyxin B, the decongestant Oxedrine, and the preservative Phenylmercuric Nitrate. The combination of Framycetin (an aminoglycoside) and Polymyxin B (a polypeptide) provides broad-spectrum anti-bacterial action by targeting bacteria through two different mechanisms. The overall general purpose of this composition is to provide a comprehensive treatment for localized issues, integrating both infection control and symptom relief. A typical use scenario involves managing localized infection where the dual action helps address bacteria while simultaneously relieving the associated congestion and pressure.

Regulatory References

  1. Polymyxin B Combination Efficacy

What side effects are possible with Omnicol?

Possible Side Effects and Safety Information

The safety profile of Omnicol is documented in regulatory labeling and classifies potential effects by frequency and system-organ class, distinguishing between common local reactions and the rare risk of serious systemic toxicity. The official classification of adverse reactions primarily focuses on effects related to the application site and the potential for systemic absorption of the active components.

System-Organ Classifications and Frequency

Adverse reactions are grouped in regulatory documents:

  • Skin and Subcutaneous Tissue Disorders: Common reactions at the application site include local irritation, pruritus (itching), and contact dermatitis. Uncommon reactions include urticaria (hives).
  • Immune System Disorders: Hypersensitivity reactions are documented. Severe reactions, such as angioedema, are officially listed.
  • Ear and Labyrinth Disorders and Renal and Urinary Disorders: The potential for Ototoxicity (inner ear damage, including hearing loss) and Nephrotoxicity (kidney damage) are recognized as Rare but serious adverse reactions, associated with the Framycetin component.

Regulatory Safety Considerations

The risk of serious systemic reactions is dependent on the degree of absorption. The potential for Ototoxicity is explicitly noted to be increased in patients with a perforated tympanic membrane and is associated with prolonged or repeated use. Similarly, the risk of Nephrotoxicity is a safety consideration for individuals with known renal impairment. Additionally, prolonged or repeated treatment is officially associated with an increased risk of developing local sensitization and potential bacterial or fungal superinfection, factors addressed within the official safety documentation.

Overdose and Emergency Response

Overdose of Omnicol, typically occurring through accidental ingestion of the topical preparation, can lead to serious systemic effects due to the absorption of its fixed-dose components. The officially documented clinical manifestations are severe and affect multiple systems, necessitating immediate regulatory action.

Central Nervous System (CNS) effects may involve lethargy, somnolence, stupor, and coma, while Cardiovascular effects can include severe bradycardia and hypotension. Systemic exposure to the antibiotic components carries a risk of nephrotoxicity, presenting as signs of acute kidney injury (e.g., azotemia), and neurotoxicity, which may include permanent sensorineural hearing loss (ototoxicity).

Life-threatening outcomes include apnea and respiratory paralysis. Children 5 years of age and younger are documented as a population associated with severe adverse events following accidental ingestion of related topical formulations. Patients with impaired renal function also face an increased risk of toxicity.

Regulators mandate that emergency medical care be sought immediately in the event of suspected overdose. Official guidance requires contacting the Poison Help Line and calling emergency services if the person has collapsed, has trouble breathing, or cannot be awakened. Management is limited to symptomatic and supportive measures, with no specific antidote known, and requires hospitalization for constant observation and frequent monitoring of renal function.

Therapeutic Uses of Omnicol

Omnicol is generally used when supportive anti-bacterial action is required alongside management of symptoms related to inflammatory or irritative states. The medication is commonly used across conditions presenting with acute episodes where these symptoms become disruptive.

The medication is typically applied in addressing symptoms related to physical discomfort during acute episodes, such as otitis externa, bacterial conjunctivitis and blepharitis, or when secondary bacterial infections complicate dermatological conditions like eczema.

The focused approach may assist with easing the impact of symptoms associated with acute changes. This supportive assistance contributes to easing the overall symptom load when symptoms related to localized swelling and feelings of pressure become more noticeable.

“It assists with maintaining functional stability and supports patients during episodes of heightened discomfort by easing the acute, distressing symptoms.”


Quick Fact: Relief for Localized Swelling

The medication is applied in addressing the secondary symptoms related to inflammatory or irritative states, such as localized congestion and swelling. The combined approach supports the patient during episodes of heightened discomfort by easing the symptom burden.

Regulatory References

  1. Summary of Product Characteristics from the Irish Medicines Board

Eligibility and Restrictions for Use

Omnicol’s official population eligibility profile is determined by strict rules set forth in government regulatory labeling. These rules define who is eligible for use, who is restricted, and who is absolutely prohibited from using the medicine.


Official Population Eligibility Status

Eligibility Status Official Regulatory Rules
Contraindicated Populations Individuals with known hypersensitivity to any component (Framycetin, Polymyxin B, Oxedrine, Phenylmercuric Nitrate) or to other aminoglycoside antibiotics must not use Omnicol. Use is also contraindicated for conditions caused by viral infections (e.g., herpes simplex). Otic preparations are contraindicated if a perforated eardrum is present.
Age and Developmental Status The medicine is approved for adults and children aged 2 years and older. Use is not recommended for children under 2 years as safety and effectiveness are inadequately established in this age group.
Reproductive Status Use is not recommended for pregnant women or those intending to become pregnant. Lactating mothers should use the medicine with caution.

This regulatory framework defines clear boundaries for patient eligibility. The restrictions prioritize the exclusion of patient groups where the risk is highest due to known allergy or specific localized pathology, such as viral infections or a perforated eardrum.

What should I know about interactions with other medicines?

The official regulatory profile for Omnicol’s components documents several clinically significant interaction patterns, necessitating specific restrictions and cautions during co-administration.

Contraindicated Combinations

The sympathomimetic component, Oxedrine, carries a mandatory restriction against co-administration with Monoamine Oxidase Inhibitors (MAOIs) due to the documented risk of a severe hypertensive crisis from potentiation of sympathetic activity. The Polymyxin B component is officially required to be avoided with curariform muscle relaxants and certain other neurotoxic drugs (e.g., tubocurarine, succinylcholine, sodium citrate) because of the documented risk of precipitating respiratory paralysis via enhanced neuromuscular blockade.

Pharmacodynamic and Exposure Interactions

The antibiotic components (Framycetin and Polymyxin B) carry official warnings regarding additive toxicity risks. Co-administration with other nephrotoxic or neurotoxic drugs (e.g., Aminoglycosides, Cisplatin, certain NSAIDs) must be avoided due to the increased severity of potential organ damage. Additionally, Framycetin may decrease the excretion rate of numerous other medicines, a pharmacokinetic pattern resulting in formally increased serum levels of co-administered drugs. This risk is officially noted as being elevated in patients with impaired renal function.

Mechanism of Action

How Omnicol Works

This section details the precise biological and molecular actions of the active ingredients, outlining the mechanisms that produce the drug's primary physiological consequences.


Dual-Mechanism Anti-Infective Action: Cellular and Ribosomal Disruption

This domain covers the action of the antibiotic components, which target specific pathways involved in microbial viability. Framycetin engages the bacterial 30S ribosomal subunit, causing errors in protein synthesis which leads to bacterial cell death. Concurrently, Polymyxin B employs a detergent-like action on the Lipopolysaccharide (LPS) of susceptible Gram-negative outer membranes, leading to structural failure and leakage. This synergistic activity results in the irreversible cessation of microbial growth and viability by affecting both internal machinery and external cellular structures.


Localized Vasoconstriction via alpha1-Adrenergic Receptor Agonism

The non-antibiotic component, Oxedrine, operates by activating alpha1-adrenergic receptors located on the smooth muscle of local blood vessels. This action initiates a cascade that results in the contraction of these muscles, leading to localized vasoconstriction. This targeted modulation of the peripheral sympathetic pathway limits blood flow into the tissues, resulting in the modulation of local tissue fluid dynamics and vascular reactivity.


Parallel Mechanisms and Constraint Points

The action involves a parallel mechanistic strategy: microbial elimination and local fluid dynamics modulation occur independently but simultaneously. This combined action influences both microbial and local host physiological processes. The mechanism's functional application is naturally constrained by specific microbial factors, such as Polymyxin B's non-applicability against Gram-positive organisms, or host factors, such as the potential for tachyphylaxis (diminished response) to the alpha1-adrenergic agonism over time.

Dosage and Administration Information

How Omnicol is Used: Dosing and Administration

Omnicol, a fixed-dose combination anti-infective, is prescribed for topical administration to the eye (ophthalmic) or ear (otic). Its usage principles are designed to ensure proper localized delivery and adherence to the regimen.

Administration Routes and Dosing Schedule

Instruction Detail
Route Topical (Ophthalmic Solution/Ointment and Otic Solution)
Starting Frequency 1 to 2 drops to the affected eye every 1 to 2 hours during the initial acute phase (for 2–3 days).
Maintenance Frequency The dose is typically reduced to 3 or 4 times per day for drops, or 2 to 3 times per day for ophthalmic ointment.
Total Duration Treatment is continued for the full prescribed duration (e.g., 7 to 10 days) as outlined in the protocol, even if symptoms subside.

Procedural Instructions and Special Conditions

Correct application technique is utilized to prevent contamination and help maintain the integrity of the preparation.

Instruction Procedural Requirement
Aseptic Technique Users must not touch the applicator tip to the eye, ear, or any surface to maintain sterility.
Ocular Technique After instilling drops, users are instructed to apply gentle pressure to the inner corner of the eye (tear duct) for 1–2 minutes.
Missed Dose Rule Apply the missed dose as soon as possible, but do not use a double dose to make up for the missed one.
Pediatric Use The appropriate dose and use must be determined by a healthcare professional, especially for infants and very young children.

These instructions establish a two-phase treatment schedule and specific application steps. This protocol governs the standardized use of the medicine, dictating the frequency, duration, and method of application.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Omnicol


Evidence for Use in Acute External Ear Infections (Otitis Externa)

Research exploring the use of Omnicol and similar topical combinations for acute external ear infections has primarily consisted of short-term Randomized Controlled Trials (RCTs). These studies were designed to examine how patient outcomes changed when using the fixed-dose combination compared to using other topical antibiotics or non-drug standard treatments. Outcomes monitored in these research settings included clinical cure rates, which tracked the resolution of infection signs, and symptom change, used in research exploring how symptoms change over time, such as measured shifts in pain, swelling, and discharge.

Studies explored what happens during periods of increased symptom activity in patients with this condition. Findings describe patterns observed in the studies over the short treatment period. Research also monitored the effect on the bacteria itself, looking for patterns of microbiological clearance—that is, the reduction or eradication of the target bacterial load in the ear canal. Studies focusing on the distinct contribution of the decongestant component, Oxedrine, to the overall clinical outcome are limited compared to those for the anti-bacterial actions.


Evidence for Use in Other Localized Bacterial Infections

The evidence base for Omnicol in other localized uses, such as certain eye and skin infections, relies more heavily on laboratory studies and data extrapolated from similar topical anti-infective combinations. Laboratory research examined the two antibiotics, Framycetin and Polymyxin B, and found that the combination covers a wide range of bacteria commonly associated with these types of infections.

Clinical evidence for these indications was often derived from research exploring short-term symptom changes in observational settings or non-comparative trials. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as localized swelling, discharge, and discomfort. Long-term effects are not fully established because the study designs did not include extended observation periods, meaning there is limited information on recurrence prevention or the durability of the measured responses over many months.

Key Studies & References

  1. Summary of Product Characteristics for Otic/Ophthalmic combinations (Example: Sofradex or similar combination containing Framycetin and an anti-inflammatory agent)

Frequently Asked Questions (FAQ)

Common questions about Omnicol (FAQ)

Q: How quickly does Omnicol start working?

A: Official documents describe a high initial dosing frequency, such as application every one to two hours during the acute phase. This frequency suggests the effects of components like the localized vasoconstrictor (which reduces swelling) may be intended to act promptly or have a short duration, necessitating frequent use to maintain the effect.

Q: How long do the effects of Omnicol last?

A: The official dosing schedule defines how often the medicine should be used. This schedule transitions from frequent application (e.g., every 1–2 hours) to less frequent use (e.g., 3–4 times per day) for maintenance, which reflects the expected duration of the medicine's therapeutic effect from a single application.

Q: What is the most common side effect reported with Omnicol?

A: According to official safety labeling, the most common reported reactions are typically localized effects at the application site. These are officially classified as local irritation, pruritus (itching), and contact dermatitis.

Q: Will Omnicol make me feel tired or drowsy?

A: Official regulatory documents track all systemic effects, including those affecting the Central Nervous System (CNS) like somnolence or dizziness. When these effects are commonly reported, they are formally included in the medicine's Adverse Reactions section.

Q: Does Omnicol interact with common pain relievers like Tylenol or Advil?

A: Official labeling contains warnings about combining Omnicol with other nephrotoxic (kidney-damaging) drugs, which includes certain drug classes like Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as Advil or Ibuprofen. This is a safety consideration associated with the potential for increased organ damage related to one of the antibiotic components.

Q: Is Omnicol suitable for older adults?

A: Regulatory information typically addresses the use of medicine in the geriatric population. Official labeling may state whether specific cautions or dose considerations apply to older adults, particularly those with reduced organ function, such as impaired kidney function.

Q: Can I take Omnicol if I have a history of heart issues?

A: Because one component, Oxedrine, is a sympathomimetic agent that acts to constrict blood vessels, official documents include precautions or warnings for patients with pre-existing cardiovascular conditions, such as high blood pressure or heart disease, as this action is a documented concern related to the Oxedrine component.

Q: Why does the official document mention a specific warning about a certain population?

A: These warnings are documented because certain conditions can increase the systemic absorption of the medicine, which raises the rare but serious safety consideration of inner ear or kidney damage (ototoxicity/nephrotoxicity).

Q: Can Omnicol be crushed or split?

A: Official administration instructions specify the product is provided as specialized liquid preparations, such as solutions or suspensions. The official use is administration of the original, liquid formulation, and precise application techniques are detailed for drops or ointment.

Q: Does Omnicol cause weight gain?

A: Official safety labeling includes a dedicated section for Adverse Reactions categorized by system-organ class. If weight gain were a known effect, it would be formally listed under the category for 'Metabolism and nutrition disorders' or 'Endocrine disorders'.

Q: Can Omnicol affect my sleep?

A: Effects on sleep, such as insomnia or drowsiness, are tracked in the official Adverse Reactions section under categories like Psychiatric or Nervous System disorders.

Q: Can I drink alcohol while taking Omnicol?

A: Official regulatory documents contain specific, explicit statements regarding alcohol consumption if any harmful interactions are known to occur or if consumption is otherwise restricted during treatment.

Q: Are there any foods I should avoid when using Omnicol?

A: Official prescribing information will specifically list any known interactions with foods or beverages if they are shown to affect the drug's safety or absorption. If no specific interaction is listed in the official product information, dietary restrictions are not formally documented.

Q: Is it safe to take Omnicol with my blood pressure medicine?

A: Regulatory documents mention interactions with cardiovascular drugs, as the Oxedrine component is a sympathomimetic agent that causes localized vasoconstriction, and this action is noted in relation to blood pressure management.

Q: Does Omnicol interact with any supplements or vitamins?

A: The official interaction sections detail known drug-drug interactions. They may also contain general warnings or disclaimers if specific supplements or herbal products are known to affect how the body processes the medicine.

Q: Can I take Omnicol if I have liver problems?

A: Official product information is required to include specific warnings or dose adjustments for patients with known hepatic (liver) impairment if the medicine's breakdown or elimination is significantly impacted by liver function.

Q: What is the risk of dependence or addiction with Omnicol?

A: Official regulatory labeling contains explicit, formal statements regarding the potential for dependence, abuse, or withdrawal phenomena if such risks are known to be associated with any of the active ingredients.

Q: What does the research say about Omnicol's long-term use?

A: The research evidence summary indicates that clinical trials often focused on short-term outcomes. As a result, the official evidence states that the long-term effects are not fully established, meaning there is limited formal information available on recurrence prevention or the durability of measured responses over many months.

Q: Are there different strengths or forms of Omnicol available?

A: The official documentation and product information list all approved strengths (e.g., concentration levels) and pharmaceutical forms (such as solution, ointment, or suspension) that are approved and marketed for this product.

Q: Is it normal to feel slightly nauseous after starting Omnicol?

A: The official safety profile lists all known side effects, categorized by how often they occur. Nausea, if reported, would be formally listed in the Adverse Reactions section under the category for 'Gastrointestinal disorders' and assigned a frequency rating.

Q: Do I need to take Omnicol with food?

A: Official prescribing information explicitly states whether the medicine must be taken with or without food for appropriate absorption or to reduce potential irritation. Since this is a topical product, specific food requirements related to absorption or systemic effect are not usually stated in the administration instructions.

Q: Is there a generic version of Omnicol available?

A: Governmental sources, such as the FDA's Orange Book or similar regulatory drug databases, officially track whether therapeutically equivalent generic versions of the drug have been approved for use.

Q: What is the difference between the brand name and generic versions of Omnicol?

A: Official governmental drug registers classify generic and brand-name drugs that are considered therapeutically equivalent. This means they are required to contain the same active ingredients, strength, dosage form, and route of administration.

Q: Does taking Omnicol impact the effectiveness of birth control pills?

A: The official product documentation includes a dedicated section to list any known interactions between the medicine and hormonal contraceptives if such an interaction is demonstrated to affect the contraceptive's effectiveness.

Q: What if I'm allergic to one of the inactive ingredients in Omnicol?

A: Official prescribing information states that known hypersensitivity (severe allergic reaction) to any component of the product, whether active or inactive, is an official contraindication for use.

Q: Are there any required tests or monitoring while taking Omnicol?

A: Official documents require specific patient monitoring (e.g., hearing tests or renal function tests) if the drug carries a risk of organ toxicity, especially when the drug is used for prolonged or repeated treatment periods.

Q: Why is Omnicol a prescription-only medicine?

A: Its status as a prescription-only medicine is due to regulatory requirements which ensure its benefits outweigh its risks under professional supervision. This is necessary because of the potential for rare serious side effects, such as ototoxicity, and the need to correctly diagnose the underlying infection (e.g., to rule out viral infections).

Q: Does Omnicol affect laboratory test results?

A: Official documents list any known drug-test interferences where the active ingredients may cause false-positive or false-negative results for specific laboratory or diagnostic tests.

Q: What are the official guidelines regarding driving or operating machinery while on Omnicol?

A: Official product information includes explicit statements on the medicine's known effects on the ability to drive and use machines. This is based on whether the medicine is known to cause visual disturbances, dizziness, or other impairments.

Q: Does the time of day matter when taking Omnicol?

A: The official dosing schedule specifies the frequency of application (e.g., 3–4 times per day) but does not mandate a specific time of day for administration unless the medicine's mechanism or side effects require morning or evening application.

Q: Why do some people say Omnicol didn't work for them?

A: Official information mentions that the effectiveness of the antibiotic components is limited by specific microbial factors, such as the non-applicability against certain bacteria. The potential for a diminished response (or tachyphylaxis) with the decongestant component over time is also noted.

Q: Does Omnicol cause any mood changes?

A: Any known changes to mood or psychological well-being, such as agitation or depression, are formally listed in the official Adverse Reactions section under the system organ class for 'Psychiatric disorders'.

Q: Is there an official patient information leaflet for Omnicol I can read?

A: Governmental regulatory bodies publish official, publicly available patient information leaflets (PILs) or Medication Guides for all approved medicines. These documents contain the official, patient-friendly information on proper use and the safety profile.

Q: What is the significance of the black box warning on Omnicol's labeling?

A: If a Black Box Warning is present, it signifies the most serious type of safety warning issued for an approved medicine. Its purpose is to draw attention to potential serious or life-threatening risks associated with the drug, such as the known Ototoxicity (inner ear damage) or Nephrotoxicity (kidney damage) risks associated with one of the components.

How should Omnicol be stored and disposed of?

How to Store and Dispose of Omnicol?

The storage and disposal instructions for Omnicol powder for oral solution are detailed in the official regulatory labeling.

Requirement Type Official Labeled Condition
Storage Temperature The unopened sachet does not require special storage conditions (e.g., store at room temperature).
Post-Reconstitution Stability The reconstituted solution must be stored well covered in a refrigerator (2°C–8°C) and is stable for only 6 hours.
Protection and Container Must be kept out of the sight and reach of children.
Disposal Any unused solution must be discarded within 6 hours of preparation. Any unused medicinal product or waste material must be disposed of in accordance with local requirements.

These statements define how the medicine must be protected from environmental factors and children. The product's stability is strictly time-limited after preparation, requiring refrigeration and mandatory disposal within six hours. Final disposal must adhere to local pharmaceutical waste regulations, ensuring proper handling of all unused material.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omnicol found in:

A-Z Index: